2nd April 2019 – Can-Fite BioPharma Limited issued an announcement, which is summarized as follows: :
BioPharma Limited announced that it has entered into a definitive agreement
with certain institutional investors to receive gross proceeds of approximately
will issue 4,923,078 registered American Depository Shares (ADSs) of Can-Fite
at a purchase price of $0.65 per ADS in a registered direct offering.
Additionally, for each ADS purchased by investors, the investors will receive
an unregistered warrant to purchase one ADS. The warrants will have an exercise
price of $0.86 per ADS, will be immediately exercisable and will expire five
years from the issuance date. The closing of the offering is expected to take
place on or about April 4, 2019.